Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW phase II study of enpatoran in systemic or cutaneous lupus erythematosus
MOH_2022-12-25_012254Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and discoid lupus erythematosus (DLE) (4 arms), sponsored by Merck KGaA. Started Nov 2022; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on MOH_2022-12-25_012254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-25_012254.